425 related articles for article (PubMed ID: 31027693)
41. Should stereotactic body radiotherapy doses be adjusted according to tumor size in early-stage non-small-cell lung cancer? A systematic review and meta-analysis.
Luo H; Cui Y; Song H; Mao R; Gao Q; Ge H
Future Oncol; 2019 Sep; 15(26):3071-3079. PubMed ID: 31426674
[No Abstract] [Full Text] [Related]
42. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.
Schonewolf CA; Heskel M; Doucette A; Singhal S; Frick MA; Xanthopoulos EP; Corradetti MN; Friedberg JS; Pechet TT; Christodouleas JP; Levin W; Berman A; Cengel KA; Verma V; Hahn SM; Kucharczuk JC; Rengan R; Simone CB
Clin Lung Cancer; 2019 Jan; 20(1):e63-e71. PubMed ID: 30337269
[TBL] [Abstract][Full Text] [Related]
43. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
[TBL] [Abstract][Full Text] [Related]
44. Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer.
Baine MJ; Verma V; Schonewolf CA; Lin C; Simone CB
Lung Cancer; 2018 Apr; 118():20-26. PubMed ID: 29571997
[TBL] [Abstract][Full Text] [Related]
45. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.
Kann BH; Miccio JA; Stahl JM; Ross R; Verma V; Dosoretz AP; Park HS; Shafman TD; Gross CP; Yu JB; Decker RH
Radiother Oncol; 2019 Mar; 132():188-196. PubMed ID: 30391106
[TBL] [Abstract][Full Text] [Related]
46. Prognostic factors for local control of stage I non-small cell lung cancer in stereotactic radiotherapy: a retrospective analysis.
Shirata Y; Jingu K; Koto M; Kubozono M; Takeda K; Sugawara T; Kadoya N; Matsushita H
Radiat Oncol; 2012 Oct; 7():182. PubMed ID: 23110967
[TBL] [Abstract][Full Text] [Related]
47. Five- Versus Ten-Fraction Regimens of Stereotactic Body Radiation Therapy for Primary and Metastatic NSCLC.
Steber CR; Hughes RT; Soike MH; Jacobson T; Helis CA; Farris JC; Farris MK
Clin Lung Cancer; 2021 Jan; 22(1):e122-e131. PubMed ID: 33046359
[TBL] [Abstract][Full Text] [Related]
48. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
[TBL] [Abstract][Full Text] [Related]
49. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
[TBL] [Abstract][Full Text] [Related]
50. Use of frailty to predict survival in elderly patients with early stage non-small-cell lung cancer treated with stereotactic body radiation therapy.
Franco I; Chen YH; Chipidza F; Agrawal V; Romano J; Baldini E; Chen A; Colson Y; Hou Y; Kozono D; Wee J; Mak R
J Geriatr Oncol; 2018 Mar; 9(2):130-137. PubMed ID: 28941581
[TBL] [Abstract][Full Text] [Related]
51. Definitive Radiotherapy for Inoperable Stage IIB Non-small-cell Lung Cancer: Patterns of Care and Comparative Effectiveness.
Jacobs CD; Gao J; Wang X; Clarke JM; Tong B; Ready NE; Suneja G; Kelsey CR; Torok JA
Clin Lung Cancer; 2020 May; 21(3):238-246. PubMed ID: 31757764
[TBL] [Abstract][Full Text] [Related]
52. A national cancer database analysis on stereotactic body radiation therapy of head and neck cancers.
Park JJ; Qureshi MM; Lam CM; Faden DL; Truong MT
Am J Otolaryngol; 2021; 42(3):102913. PubMed ID: 33460976
[TBL] [Abstract][Full Text] [Related]
53. Clinical Outcomes and Predictors of Lung Toxicity After Multiple Courses of Lung Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
Muller DA; Dutta SW; Aliotta E; Sanders JC; Wijesooriya K; Watkins WT; Larner JM
Clin Lung Cancer; 2021 May; 22(3):234-241. PubMed ID: 32690439
[TBL] [Abstract][Full Text] [Related]
54. Stereotactic Body Radiation Therapy and the Influence of Chemotherapy on Overall Survival for Large (≥5 Centimeter) Non-Small Cell Lung Cancer.
Verma V; McMillan MT; Grover S; Simone CB
Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):146-154. PubMed ID: 27843029
[TBL] [Abstract][Full Text] [Related]
55. Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis.
Foster CC; Rusthoven CG; Sher DJ; Feldman L; Pasquinelli M; Spiotto MT; Koshy M
Lung Cancer; 2019 Apr; 130():162-168. PubMed ID: 30885339
[TBL] [Abstract][Full Text] [Related]
56. 30 Gy or 34 Gy? Comparing 2 single-fraction SBRT dose schedules for stage I medically inoperable non-small cell lung cancer.
Videtic GM; Stephans KL; Woody NM; Reddy CA; Zhuang T; Magnelli A; Djemil T
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):203-8. PubMed ID: 25015198
[TBL] [Abstract][Full Text] [Related]
57. Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center.
Rosen LR; Fischer-Valuck BW; Katz SR; Durci M; Wu HT; Syh J; Syh J; Patel B
Tumori; 2014; 100(1):42-8. PubMed ID: 24675490
[TBL] [Abstract][Full Text] [Related]
58. Comparison of Long-term Survival of Patients With Early-Stage Non-Small Cell Lung Cancer After Surgery vs Stereotactic Body Radiotherapy.
Chi A; Fang W; Sun Y; Wen S
JAMA Netw Open; 2019 Nov; 2(11):e1915724. PubMed ID: 31747032
[TBL] [Abstract][Full Text] [Related]
59. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
[TBL] [Abstract][Full Text] [Related]
60. Predictors of Distant Failure After Stereotactic Body Radiation Therapy for Stages I to IIA Non-Small-Cell Lung Cancer.
Miller CJ; Martin B; Stang K; Hutten R; Alite F; Small C; Emami B; Harkenrider MM
Clin Lung Cancer; 2019 Jan; 20(1):37-42. PubMed ID: 30279109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
